RU2005118419A - Вакцина против вируса лихорадки западного нила - Google Patents

Вакцина против вируса лихорадки западного нила Download PDF

Info

Publication number
RU2005118419A
RU2005118419A RU2005118419/13A RU2005118419A RU2005118419A RU 2005118419 A RU2005118419 A RU 2005118419A RU 2005118419/13 A RU2005118419/13 A RU 2005118419/13A RU 2005118419 A RU2005118419 A RU 2005118419A RU 2005118419 A RU2005118419 A RU 2005118419A
Authority
RU
Russia
Prior art keywords
amino acid
nucleic acid
acid molecule
substitution
west nile
Prior art date
Application number
RU2005118419/13A
Other languages
English (en)
Other versions
RU2376374C2 (ru
Inventor
Хуан АРРОЙО (US)
Хуан АРРОЙО
Чарльз М. МИЛЛЕР (US)
Чарльз М. МИЛЛЕР
Джон Аврам КАТАЛАН (US)
Джон Аврам КАТАЛАН
Томас П. МОНАТ (US)
Томас П. Монат
Original Assignee
Экэмбис, Инк. (Us)
Экэмбис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экэмбис, Инк. (Us), Экэмбис, Инк. filed Critical Экэмбис, Инк. (Us)
Publication of RU2005118419A publication Critical patent/RU2005118419A/ru
Application granted granted Critical
Publication of RU2376374C2 publication Critical patent/RU2376374C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

1. Молекула нуклеиновой кислоты, содержащая последовательности, кодирующие предмембранные и оболочечные белки вируса Западного Нила и капсидные и неструктурные белки вируса желтой лихорадки, где указанный предмембранный или оболочечный белок содержит аттенуирующую мутацию.
2. Молекула нуклеиновой кислоты по п. 1, где указанная аттенуирующая мутация включает аминокислотную замену в положении, выбранном из группы, включающей положения 107, 316 и 440 оболочечного белка.
3. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положении 107.
4. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положении 316 и положении 440.
5. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положениях аминокислот 107, 316 и 440.
6. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 107 представляет собой замену лейцина на фенилаланин или консервативную аминокислоту.
7. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 316 представляет собой замену аланина на валин или консервативную аминокислоту.
8. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 440 представляет собой замену лизина на аргинин или консервативную аминокислоту.
9. Химерный флавивирус, кодируемый молекулой нуклеиновой кислоты по п. 1.
10. Способ индуцирования иммунного ответа на вирус Западного Нила у субъекта, где указанный способ включает введение субъекту химерного флавивируса по п.9.
11. Способ по п. 10, где указанный субъект подвергается риску развития, но не имеет ее, инфекции, вызываемой вирусом Западного Нила.
12. Способ по п. 10, где указанный субъект инфицирован вирусом Западного Нила.
13. Способ получения химерной флавивирусной вакцины, включающий введение молекулы нуклеиновой кислоты по п. 1 в клетки.
14. Применение химерного флавивируса по п. 9 для вакцинации против вируса Западного Нила.
RU2005118419/13A 2002-11-15 2003-11-13 Вакцина против вируса лихорадки западного нила RU2376374C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42659202P 2002-11-15 2002-11-15
US60/426,592 2002-11-15

Publications (2)

Publication Number Publication Date
RU2005118419A true RU2005118419A (ru) 2006-01-20
RU2376374C2 RU2376374C2 (ru) 2009-12-20

Family

ID=32326380

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005118419/13A RU2376374C2 (ru) 2002-11-15 2003-11-13 Вакцина против вируса лихорадки западного нила

Country Status (16)

Country Link
US (2) US7507415B2 (ru)
EP (1) EP1575979B1 (ru)
JP (1) JP4683926B2 (ru)
KR (1) KR101150584B1 (ru)
AT (1) ATE452900T1 (ru)
AU (1) AU2003290985B2 (ru)
BR (1) BRPI0316346B1 (ru)
CA (1) CA2505942C (ru)
DE (1) DE60330708D1 (ru)
ES (1) ES2337893T3 (ru)
HK (1) HK1083192A1 (ru)
IL (2) IL168584A (ru)
MX (1) MXPA05005140A (ru)
RU (1) RU2376374C2 (ru)
WO (1) WO2004045529A2 (ru)
ZA (1) ZA200503871B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691550B2 (en) 2004-10-20 2014-04-08 Sanofi Pasteur Biologics, Llc Vaccines against japanese encephalitis virus and west nile virus

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
KR100921592B1 (ko) * 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
BRPI0306905B8 (pt) * 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
ES2337893T3 (es) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. Vacuna del virus del nilo occidental.
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2005320001B2 (en) 2004-12-24 2011-05-19 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
US8017754B2 (en) * 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
US7888069B2 (en) * 2006-12-22 2011-02-15 Dow Agrosciences Llc Plant-made west nile virus (WNV) vaccines, vectors and plant codon optimized sequences
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
NZ603854A (en) * 2008-08-29 2015-03-27 Boehringer Ingelheim Vetmed West nile virus vaccine
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
US8889148B2 (en) 2010-07-01 2014-11-18 Research Development Foundation Flavivirus host-range mutations and uses thereof
AU2012229192B2 (en) 2011-03-14 2017-04-20 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
KR100921592B1 (ko) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
NZ532385A (en) 2001-10-19 2007-01-26 Acambis Inc Methods of preventing and treating flavivirus infection in animals
DE20120256U1 (de) * 2001-12-14 2002-03-07 Haefele Gmbh & Co Beschlag
BRPI0306905B8 (pt) 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ES2337893T3 (es) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. Vacuna del virus del nilo occidental.
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (fr) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691550B2 (en) 2004-10-20 2014-04-08 Sanofi Pasteur Biologics, Llc Vaccines against japanese encephalitis virus and west nile virus

Also Published As

Publication number Publication date
RU2376374C2 (ru) 2009-12-20
BRPI0316346B1 (pt) 2016-05-31
WO2004045529A2 (en) 2004-06-03
BR0316346A (pt) 2005-09-27
KR20050072143A (ko) 2005-07-08
IL202978A (en) 2013-11-28
AU2003290985B2 (en) 2010-04-01
ES2337893T3 (es) 2010-04-30
ATE452900T1 (de) 2010-01-15
EP1575979B1 (en) 2009-12-23
IL202978A0 (en) 2011-08-01
JP4683926B2 (ja) 2011-05-18
US7507415B2 (en) 2009-03-24
MXPA05005140A (es) 2005-08-19
US8088391B2 (en) 2012-01-03
AU2003290985A1 (en) 2004-06-15
CA2505942C (en) 2012-03-13
US20070275015A9 (en) 2007-11-29
US20100086564A1 (en) 2010-04-08
ZA200503871B (en) 2006-08-30
KR101150584B1 (ko) 2012-06-27
JP2006506092A (ja) 2006-02-23
US20050053624A1 (en) 2005-03-10
DE60330708D1 (de) 2010-02-04
CA2505942A1 (en) 2004-06-03
IL168584A (en) 2010-12-30
HK1083192A1 (en) 2006-06-30
EP1575979A4 (en) 2006-06-21
WO2004045529A3 (en) 2004-08-26
EP1575979A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
RU2005118419A (ru) Вакцина против вируса лихорадки западного нила
JP5006782B2 (ja) 弱毒ペスチウイルスを含むワクチン
ES2757927T3 (es) Virus de la peste porcina clásica (VPPC) recombinante que comprende sustituciones en el epítopo TAV de la proteína E2
US20180228887A1 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2004520406A (ja) 弱毒生ワクチン
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
WO2012038454A1 (en) Bvdv vaccine
ES2644801T3 (es) Antígenos de vacuna quimérica contra el virus de la hepatitis c
BR0112020A (pt) Partìculas tipo vìrus de bvdv
US20230149528A1 (en) Development of mosaic vaccines against foot and mouth disease virus serotype o
KR100902197B1 (ko) 티모신에 의한 유전적 면역화 증대
WO2023006131A1 (es) Antigeno recombinante para la induccion de respuesta inmune contra el virus zika
CN115925828A (zh) 猪瘟病毒重组蛋白及其应用
WO2007103565A2 (en) Wnv dna vaccine incorporating a cmv/r backbone and expressing wnv prm and e proteins
Yokosuka et al. High detection rate of hepatitis C virus E2 antibody in patients with type C hepatitis
Shahana et al. Enhancement of Japanese Encephalitis Virus DNA vaccine efficacy by using Mycobacterium avium paratuberculosis heat shock protein 65

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181114